MedTrace Logo

HepaSphere Chemoembolization in Advanced HCC Patients: Safety & Efficacy Registry in China

NCT02743065 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2018-09-20

No results posted yet for this study

Summary

The purpose of this multicenter registry is to gather the safety, efficacy and survival data in advanced HCC patients treated with HepaSphere in China in order to evaluate the application of HepaSphere deTACE in treating advanced HCC patients

Conditions

Interventions

DEVICE

HepaSphere with 50-75mg Doxorubicin

HepaSphere with 50-75mg Doxorubicin

Sponsors & Collaborators

  • Third Affiliated Hospital, Sun Yat-Sen University

    collaborator OTHER

  • Fifth Affiliated Hospital, Sun Yat-Sen University

    lead OTHER

Principal Investigators

  • Hong Shan, MD · Fifth Affiliated Hospiatl, Sun Yet-Sen University

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-09-30
Primary Completion
2019-06-30
Completion
2019-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02743065 on ClinicalTrials.gov